Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the prospective ARMYDA-AGEs study)

American Journal of Cardiology

Volumn 112, Issue 1, 2013, Pages 21-26

  Spadaccio, Cristiano ^a   Patti, Giuseppe ^a   De Marco, Federico ^b   Coccia, Raffaella ^c   Di Domenico, Fabio ^c   Pollari, Francesco ^a   Zanzonico, Roberta ^a   Pettinari, Matteo ^d   Lusini, Mario ^a   Di Sciascio, Germano ^a   Covino, Elvio ^a   Chello, Massimo ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SULFANILAMIDE DERIVATIVE;

ADULT; ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES CONTROL; DRUG ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; STABLE ANGINA PECTORIS;

AGED; ANGINA, STABLE; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PYRROLES; ROC CURVE; TUBULIN MODULATORS;

EID: 84879099031     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.02.046     Document Type: Conference Paper

References (30)

1. R.A. Corpus, P.B. George, J.A. House, S.R. Dixon, S.C. Ajluni, W.H. Devlin, G.C. Timmis, M. Balasubramaniam, and W.W. O'Neill Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention J Am Coll Cardiol 43 2004 8 14
2. M.O. Lima-Filho, G.L. Figueiredo, M.C. Foss-Freitas, M.C. Foss, and J.A. Marin-Neto Predictors of restenosis after percutaneous coronary intervention using bare-metal stents: a comparison between patients with and without dysglycemia Braz J Med Biol Res 43 2010 572 579
3. G. Lemesle, L. Bonello, A. de Labriolle, G. Maluenda, A.I. Syed, S.D. Collins, I. Ben-Dor, R. Torguson, K. Kaneshige, Z. Xue, W.O. Suddath, L.F. Satler, K.M. Kent, J. Lindsay, A.D. Pichard, and R. Waksman Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation Am J Cardiol 104 2009 41 45
4. M. Chello, C. Spadaccio, M. Lusini, E. Covino, C. Blarzino, F. De Marco, F. Di Domenico, and R. Coccia Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure Diabetes Metab Res Rev 25 2009 420 426
5. S.J. Kang, G.S. Mintz, D.W. Park, S.W. Lee, Y.H. Kim, C. Whan Lee, K.H. Han, J.J. Kim, S.W. Park, and S.J. Park Mechanisms of in-stent restenosis after drug-eluting stent implantation: intravascular ultrasound analysis Circ Cardiovasc Interv 4 2011 9 14
6. W.W. O'Neill, and M.B. Leon Drug-eluting stents: costs versus clinical benefit Circulation 107 2003 3008 3011
7. Y. Xie, S.J. You, Y.L. Zhang, Q. Han, Y.J. Cao, X.S. Xu, Y.P. Yang, J. Li, and C.F. Liu Protective role of autophagy in AGE-induced early injury of human vascular endothelial cells Mol Med Report 4 2011 459 464
8. M. Kalousova, K. Bartosova, T. Zima, J. Skibova, V. Teplan, and O. Viklicky Pregnancy-associated plasma protein a and soluble receptor for advanced glycation end products after kidney transplantation Kidney Blood Press Res 30 2007 31 37
9. R. Sampathkumar, M. Balasubramanyam, M. Rema, C. Premanand, and V. Mohan A novel advanced glycation index and its association with diabetes and microangiopathy Metabolism 54 2005 1002 1007
10. S. Horiuchi, N. Araki, and Y. Morino Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure J Biol Chem 266 1991 7329 7332
11. C. Chan, R. Zambahari, U. Kaul, C.P. Lau, H. Whitworth, S. Cohen, and M. Buchbinder A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study Catheter Cardiovasc Interv 72 2008 591 600
12. M. Stern, A. O'Meara, L. Infanti, J.P. Sigle, and A. Buser Prognostic value of red blood cell parameters and ferritin in predicting deferral due to low hemoglobin in whole blood donors Ann Hematol 91 2012 775 780
13. A. Goldin, J.A. Beckman, A.M. Schmidt, and M.A. Creager Advanced glycation end products: sparking the development of diabetic vascular injury Circulation 114 2006 597 605
14. N. Ahmed, and P.J. Thornalley Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 9 2007 233 245
15. R.J. McCarter, J.M. Hempe, and S.A. Chalew Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial Diabetes Care 29 2006 352 355
16. A.B. Kauffman, T. Delate, K.L. Olson, A.A. Cymbala, K.A. Hutka, S.L. Kasten, and J.R. Rasmussen Relationship between haemoglobin A1C values and recurrent cardiac events: a retrospective, longitudinal cohort study Clin Drug Investig 28 2008 501 507
17. J. Lindsay, A.K. Sharma, D. Canos, M. Nandalur, E. Pinnow, S. Apple, G. Ruotolo, M. Wijetunga, and R. Waksman Preprocedure hyperglycemia is more strongly associated with restenosis in diabetic patients after percutaneous coronary intervention than is hemoglobin A1C Cardiovasc Revasc Med 8 2007 15 20
18. C.J. O'Sullivan, N. Hynes, B. Mahendran, E.J. Andrews, G. Avalos, S. Tawfik, A. Lowery, and S. Sultan Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome? Eur J Vasc Endovasc Surg 32 2006 188 197
19. N. Ahmed Advanced glycation endproducts-role in pathology of diabetic complications Diabetes Res Clin Pract 67 2005 3 21
20. A. Pfutzner, N. Marx, G. Lubben, M. Langenfeld, D. Walcher, T. Konrad, and T. Forst Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study J Am Coll Cardiol 45 2005 1925 1931
21. D. Aronson Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure Med Hypotheses 59 2002 297 301
22. V. Pasceri, G. Patti, G. Speciale, C. Pristipino, G. Richichi, and G. Di Sciascio Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction Am Heart J 153 2007 749 754
23. J.C. Townsend, P. Rideout, and D.H. Steinberg Everolimus-eluting stents in interventional cardiology Vasc Health Risk Manag 8 2012 393 404
24. G. Basta, G. Lazzerini, M. Massaro, T. Simoncini, P. Tanganelli, C. Fu, T. Kislinger, D.M. Stern, A.M. Schmidt, and R. De Caterina Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses Circulation 105 2002 816 822
25. K. Wang, Z. Zhou, M. Zhang, L. Fan, F. Forudi, X. Zhou, W. Qu, A.M. Lincoff, A.M. Schmidt, E.J. Topol, and M.S. Penn Peroxisome proliferator- activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model J Pharmacol Exp Ther 317 2006 37 43
26. H. Bai, J. Masuda, Y. Sawa, S. Nakano, R. Shirakura, Y. Shimazaki, J. Ogata, and H. Matsuda Neointima formation after vascular stent implantation. Spatial and chronological distribution of smooth muscle cell proliferation and phenotypic modulation Arterioscler Thromb 14 1994 1846 1853
27. E.Y. Choi, H.M. Kwon, C.W. Ahn, G.T. Lee, B. Joung, B.K. Hong, Y.W. Yoon, D. Kim, K.H. Byun, T.S. Kang, S.J. Yoon, S.W. Kwon, S.J. Lee, J.K. Park, and H.S. Kim Serum levels of advanced glycation end products are associated with in-stent restenosis in diabetic patients Yonsei Med J 46 2005 78 85
28. L. Lu, L. Jin Pu, Q.J. Chen, L. Wang, W. Peng, X. Yan, Q. Zhang, R. Yan Zhang, P.H. Gong, J.P. Qiu, and W.F. Shen Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients Clin Chim Acta 396 2008 33 37
29. K. Takenaka, S. Yamagishi, T. Matsui, K. Nakamura, and T. Imaizumi Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes Curr Neurovasc Res 3 2006 73 77
30. H.J. Park, S.M. Seo, W.S. Shin, H.Y. Kim, Y.S. Choi, Y.S. Koh, S.G. Youn, M.W. Park, K. Chang, P.J. Kim, H.O. Jung, S.H. Baek, W.S. Chung, K.B. Seung, and K.D. Yoo Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents Coron Artery Dis 22 2011 12 17